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Abstract
Objective: Large studies describing the profile of high-risk Human papillomavirus (hrHPV) genotypes among women in sub-
Saharan Africa are lacking. Here we describe the prevalence and distribution of hrHPV genotypes among HIV-negative
women in South Africa, with and without cervical intraepithelial neoplasia (CIN).
Methods: We report data on 8,050 HIV-negative women, aged 17–65 years, recruited into three sequential studies
undertaken in Cape Town, South Africa. Women had no history of previous cervical cancer screening. Cervical samples were
tested for hrHPV DNA using the Hybrid Capture 2 (HC2) assay and all positive samples were genotyped using a PCR-based
assay (Line Blot). Women underwent colposcopy and biopsy/endocervical curettage to determine CIN status. The
prevalence and distribution of specific hrHPV genotypes were examined by age and CIN status.
Results: Overall, 20.7% (95% CI, 19.9–21.6%) of women were hrHPV-positive by HC2, with women with CIN having the
highest rates of positivity. Prevalence decreased with increasing age among women without CIN; but, a bimodal age curve
was observed among women with CIN. HPV 16 and 35 were the most common hrHPV genotypes in all age and CIN groups.
HPV 45 became more frequent among older women with CIN grade 2 or 3 (CIN2,3). Younger women (17–29 years) had
more multiple hrHPV genotypes overall and in each cervical disease group than older women (40–65 years).
Conclusion: HPV 16, 35, and 45 were the leading contributors to CIN 2,3. The current HPV vaccines could significantly
reduce HPV-related cervical disease; however, next generation vaccines that include HPV 35 and 45 would further reduce
cervical disease in this population.
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Introduction
Human papillomavirus (HPV) is one of the most common
sexually transmitted infections worldwide and most women are
infected with one or more HPV genotypes at some point during
their sexual lives. Persistent HPV infection caused by high-risk
HPV (hrHPV) genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, and 68) is associated with cervical pre-malignant lesions and
cervical carcinoma, a cancer that is the second most common
malignancy among women worldwide [1,2,3]. Globally, HPV 16
and 18 are the predominant hrHPV genotypes among women
with invasive cervical cancer and cause approximately 50% and
20% of cervical cancers, respectively [4,5]. Two highly effective
prophylactic vaccines have been developed to prevent infection
with HPV 16 and 18 [6,7]. There are also several approved assays
that have been used to improve cervical cancer screening by
detecting hrHPV genotypes and determining the presence of a
specific hrHPV genotype in women [3,8]. HPV vaccination and
cervical cancer screening with hrHPV testing in combination offer
the potential of substantially reducing cervical cancer incidence in
high-risk populations.
Although the prevalence of HPV infection is particularly high in
women living in sub-Saharan Africa, studies have found that the
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proportion of high-risk infections attributable to HPV 16, the most
common high-risk type, is less among women living in sub-
Saharan Africa compared to women living in other regions of the
globe [9,10]. The lesser contribution of HPV 16 is somewhat
surprising given that the incidence and mortality rates of invasive
cervical cancer (31.7 and 22.9 per 100,000 women per year, age-
standardized, respectively) in sub-Saharan Africa are among the
highest in the world [2,11,12]. If HPV 16 contributes a lesser
proportion of hrHPV types detected in cervical disease and cancer
cases in sub-Saharan Africa compared to other geographical
regions, HPV vaccination and screening programs that utilize
HPV 16 and 18 genotyping assays to improve specificity would not
have as great of an impact as in other regions where the
proportion of disease due to HPV 16 is higher. Therefore, it is
important to better describe the prevalence of specific hrHPV
genotypes in sub-Saharan Africa women with and without cervical
disease. A description of hrHPV genotypes will allow policy
makers to identify the best strategies for reducing cervical cancer
in this region.
Several meta-analyses have described the global distribution of
HPV genotypes; however, sub-Saharan African populations
contribute only relatively small amounts of data to these analyses
[4,9]. Moreover, HPV studies conducted in Africa have been
heterogeneous in terms of age distribution, methods of ascertain-
ing cervical disease, and the extent of HIV testing. As a result, age-
and type-specific data for HIV-uninfected women of known
cervical disease status are only imprecisely determined for any sub-
Saharan African population. In this study, we described the
prevalence and distribution of hrHPV genotypes, including
multiple types, among HIV-negative women enrolled in three
sequential cervical cancer screening studies undertaken in South
Africa in which cervical disease status was rigorously determined
using repeat colposcopy and biopsy [13,14].
Methods
Study Population
This analysis is based on data from three sequential studies that
recruited women from the same three clinical sites in the peri-
urban community of Khayelitsha, outside Cape Town, South
Africa. All three studies included women who were not pregnant at
the time of enrollment, had never been screened or treated for
cervical cancer, and had not undergone a hysterectomy.
Ethics statement. All women provided written informed
consent and the protocols were approved by the Institutional
Review Boards of Columbia University, New York and the
University of Cape Town, South Africa. All clinical investigation
was conducted according to the principles expressed in the
Declaration of Helsinki.
In Cohort 1, 2,699 women (2,505 HIV-negative), aged 35–65
years, were enrolled between January 1998 and November 1999
into a study evaluating the performance of different tests for
cervical cancer screening [14]. In Cohort 2, 6,553 women (5,708
HIV-negative), aged 35–65 years, were enrolled between June
2000 and December 2002 and were followed for 36 months in a
trial examining the safety and efficacy of two screen-and-treat
approaches for cervical cancer prevention [13]. For the analyses
presented here, only women randomized to the control group
(2,165; 1,881 HIV-negative) or to the screen-and-treat arm
utilizing HPV testing (2,163; 1,874 HIV-negative) were included
due to the availability of HPV typing data. In Cohort 3, 2,998
women (2,265 HIV-negative), aged 17–34 years, were enrolled in
a study between July 2004 and June 2006 examining HPV
prevalence among younger women. There were no duplicate
women in the 3 cohorts to our knowledge. We further restricted
our study population to women with definitive cervical disease
status and excluded women with invasive cervical cancer due to
the small number of cases (n = 23), resulting in a final sample size
of 8,050 HIV-negative women (2,485 in Cohort 1, 3,353 in
Cohort 2, and 2,212 in Cohort 3).
Data Collection and Laboratory Procedures
In all three studies, a short risk factor questionnaire was
conducted at baseline and blood was collected for HIV testing. A
gynecologic examination was conducted in which cervical samples
were obtained, including a sample collected from the exo- and
endocervix using a plastic spatula and cytobrush and placed into
liquid-based cytology medium (ThinPrep PreservCyte, Hologics,
Marlborough, MA). Pap smears were evaluated at either the
University of Cape Town Cytopathology Laboratory, Health
Networks Laboratory, Allentown PA, or Columbia University,
New York, NY and classified using the Bethesda System. Hybrid
Capture 2 (HC2) DNA assay (Qiagen Corporation, Germantown,
MD, USA) was used to test cervical samples for hrHPV DNA
types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 [13].
High-risk HPV DNA positivity was based on a cut-off of relative
light units (RLU).1 times the positive control. Aliquots of the
liquid-based cytology samples were stored at 230uC for future
testing.
After the fieldwork for the studies were completed, stored
cervical samples from all women who were HC2 positive were
sought for determination of the specific hrHPV genotype present.
Of 8,050 women in the three cohorts, 1,670 tested hrHPV DNA
positive by HC2 and 1,642 (98.3%) could be located and tested to
determine the specific high risk HPV genotype present.
For hrHPV genotyping, DNA was isolated from 200 ul of the
liquid-based cytology specimen using a spin column (Qiagen Inc.,
Chatsworth, CA.). Purified DNA was analyzed for individual HPV
genotypes using a prototype polymerase chain reaction-based
(PCR) line blot assay (kindly provided by Dr. Janet Kornegay,
Roche Molecular Diagnostics, Alameda, CA) that uses the
PGMY09/11 consensus primers. If a hrHPV genotype was not
identified using the prototype line blot assay, DNA was re-isolated
and re-analyzed for individual HPV genotypes using the PCR-
based, Linear Array HPV Typing Assay (Roche Molecular
Diagnostics, Alameda, CA) [15].
Determination of Disease Status
To meet the objectives of each study, slightly different protocols
were followed to determine disease status (within normal limits
[WNL], cervical intraepithelial neoplasia [CIN] grade 1 [CIN1],
CIN grade 2 [CIN2], CIN grade 3 [CIN3]) in each cohort. In
Cohort 1, all women who had positive results on one or more of
four independent screening tests were referred for colposcopy 2–6
days after the enrollment visit. The four screening tests were HPV
DNA testing using HC2 (RLU.1x were referred), visual
inspection with acetic acid, cytology (ASCUS and above were
referred), and expert cervicography [14]. Approximately half of
the participants had one or more of the four screening tests
classified as positive and underwent colposcopy. In Cohort 2,
colposcopy was performed on all women at 6 and 12 months after
enrollment [13]. Samples for HPV DNA testing were collected at
the time of enrollment. In Cohort 3, all women underwent
colposcopy at their enrollment examination. Women not found to
have biopsy-confirmed CIN2 or greater at the initial colposcopy
who were HC2 positive, had cytology results of $ASCUS, or who
had biopsy-confirmed CIN1 lesions underwent a second colpos-
copy 12 weeks after enrollment. Thus, for both Cohorts 2 and 3,
High-Risk HPV Genotypes among Women
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all subjects underwent at least one or more colposcopy examina-
tions. Due to the fact that no cervical disease was diagnosed in
Cohort 2 or 3 among women who had both negative HPV and
cytology results, we can confirm that minimal verification bias
exists in Cohort 1. In all studies, colposcopy was conducted by
clinicians specifically trained in colposcopy and according to a
standard protocol. All abnormal areas were biopsied and
endocervical curettage specimens were collected. Biopsy and
endocervical curettage specimens were evaluated by two pathol-
ogists at Columbia University. Inconsistent diagnoses were
adjudicated in a microscopic conference and the final disease
status is based on the highest grade adjudicated pathology
diagnosis.
Data Analysis
Two parameters were calculated to describe the epidemiology
of hrHPV genotypes: (1) distribution and (2) prevalence. Distri-
bution refers to the proportion of the hrHPV infection burden
attributable to a specific genotype and was calculated in two ways:
a) utilizing the total number of women with any hrHPV type as the
denominator, and b) utilizing the total number of all hrHPV
infections as the denominator. For genotype-specific prevalence
calculations, we assumed that the HC2 assay was100% sensitive
and specific in detecting hrHPV. Thus, type-specific HPV
prevalence was calculated by multiplying the observed distribution
of a specific type by the observed HPV prevalence determined by
HC2.
HPV prevalence determined by HC2 positivity, the distribution
and prevalence of specific hrHPV genotypes, and the frequency of
multiple types was examined by cervical disease status and age
group. Pearson’s chi-square test or Fisher’s exact test (when
appropriate) were used to compare frequencies between groups in
distribution and frequency of multiple hrHPV genotypes. For
type-specific prevalence comparisons, the standard errors for the
estimates were calculated using the delta method and compared to




There were 8,050 HIV-negative women, aged 17–65 years,
included in this analysis. Table 1 describes demographic,
behavioral, and clinical characteristics by study cohort. Women
in the younger age cohort, aged 17–34 years, were more educated,
less likely to be married, more likely to be treated for a sexually
transmitted disease, and more likely to test HC2 HPV DNA
positive in comparison to women in the older age cohorts, aged
35–65 years (p,0.0001). In addition, women in the younger age
cohort were more likely to be diagnosed with CIN1 than women
in the older age cohorts. Women in the older age cohorts had
more live births and used condoms less than women in the
younger cohort (p,0.0001).
Table 1. Characteristics of 8050 HIV-negative women recruited into three cervical cancer screening studies in Khayelitsha, South
Africa.
Cohort 1 (n =2485) Cohort 2 (n =3353) Cohort 3 (n =2212)
P-value (Younger vs
Older Cohorts)
Age range 35–65 years 35–65 years 17–34 years
Median Age (25–75
percentile)
41 years (36–47 years) 42 years (38–48 years) 26 years (22–30 years) ,0.0001
N (%) ,=10 years of
Education
2243 (90.26%) 3075 (91.71%) 1223 (55.29%) ,0.0001
N (%) Currently employed 1042 (42.25%) 874 (26.07%) 603 (27.26%) ,0.0001
N (%) Smoker 128 (5.16%) 239 (7.13%) 65 (2.94%) ,0.0001
N (%) Drink alcohol in last
month
167 (6.72%) 416 (12.41%) 328 (14.83%) ,0.0001
N (%) Married 1167 (46.96%) 1789 (53.36%) 823 (37.21%) ,0.0001
Median age of 1st sexual
intercourse (range)
17 years (10–30 years) 16 years (6–39 years) 17 years (7–28 years) 0.0853
N (%) Ever treated for STD 42 (1.70%) 93 (2.77%) 523 (23.64%) ,0.0001
N (%) Ever used condoms 187 (9.08%) 236 (8.30%) 1341 (60.62%) ,0.0001
N (%) .2 live births 1653 (66.63%) 2496 (74.44%) 191 (8.63%) ,0.0001
N (%) Disease Status
WNL 2328 (93.7%) 3219 (96.0%) 2022 (91.4%) ,0.0001*
CIN 1 79 (3.2%) 52 (1.6%) 130 (5.9%)
CIN 2 41 (1.6%) 51 (1.5%) 40 (1.8%)
CIN 3 37 (1.5%) 31 (0.9%) 20 (0.9%)
N (%) HC2 HPV
DNA Positive
429 (17.26%) 572 (17.06%) 669 (30.24%) ,0.0001
Note: * = p-value of trend, STD = sexually transmitted disease, WNL =within normal limits, CIN 1 = cervical intraepithelial neoplasia grade 1, CIN 2 = cervical intraepithelial
neoplasia grade 2, CIN 3= cervical intraepithelial neoplasia grade 3, HPV=Human papillomavirus, HC2 =Hybrid capture 2, Older cohort (aged 35–65 years) = Cohorts 1
and 2 combined, Younger cohort (aged 17–34 years) = Cohort 3, Pearson’s chi-square test and Student’s T-test were used to examine differences between the older and
younger cohorts.
doi:10.1371/journal.pone.0044332.t001
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Hybrid Capture 2 (HC2) HPV DNA Positivity
Overall, HC2 HPV DNA positivity was 20.7% (95% CI, 19.9–
21.6%), with women in the younger cohort having the highest
prevalence (30.2%, 95% CI, 28.3–32.2%) in comparison to
women in the older cohorts (17.1%, 95% CI, 16.0–18.4%)
(Table1). Younger age was strongly associated with higher rates of
HC2 HPV DNA positivity among women with WNL, with a
positivity of 53.7% in women ,20 years of age. HC2 HPV DNA
positivity among women with WNL declined and stabilized
around 15% by age 30 years; and, there was no clear evidence
of a subsequent rise in older women (Figure 1). For women with
cervical disease, HC2 HPV DNA positivity was high regardless of
age with a suggestion of a U-shaped curved with the lowest rates of
HPV DNA in the 30–49 year age group and higher rates in
younger and older age categories (Figure 1).
Genotype-specific Prevalence
Of 1,670 women who tested HC2 HPV DNA positive, samples
from 1,642 (98.3%) could be located and tested to determine the
specific high risk HPV genotype present. PCR identified one or
more hrHPV genotype in 71.5% (902/1261) of women with
WNL, 86.9% (172/198) of women with CIN1, 90.3% (93/103) of
women with CIN2, and 90% (72/80) of women with CIN3. The
most common hrHPV genotypes in descending order were HPV
35, 16, 58, 45, 52 and 18. The three most common HPV
genotypes in descending order by disease status were in women
with WNL: HPV 35, HPV 16, and HPV 58; in women with
CIN1: HPV 35, HPV 16 & 51 (tied), and HPV 18, in women with
CIN2: HPV 35, HPV 16, and HPV 58; and in women with CIN
3: HPV 16, HPV 35, and HPV 45. A high-risk HPV genotype was
identified in 18 of the 23 invasive cervical cancer cases. In these 18
cases the most common genotypes were as follows: HPV 16 (56%),
HPV 18 (22%), HPV 45 & 58 (tied- 11%), and HPV 52 & 68 (tied
–6%); none had HPV 35 detected.
Among women with WNL or CIN1 (WNL/CIN1), those who
were younger (17–29 years) had a significantly higher prevalence
of 5/6 most common hrHPV genotypes than older women. In
contrast among women with CIN2 or CIN3 (CIN 2,3), younger
women only had a higher prevalence of HPV 18 and 58 than older
women. Other common types were either similar across age
groups or tended towards an increased prevalence with older age
(HPV16 and HPV45) (Figure 2).
Women with CIN 2,3 had a significantly higher prevalence of
the 6 common hrHPV genotypes than women with WNL/CIN 1
(p,0.05) in all age strata. HPV 45 and HPV 52 were the
exception among younger women (17–29 years) where there was
no significant difference in the prevalence of these types by disease
status (Table S1).
Distribution of Specific hrHPV Genotypes
Table 2 displays the distribution of genotypes among women
with at least one identified hrHPV genotype by disease status.
HPV 35 and 16 were the most common hrHPV genotypes among
women in every disease level. The proportions of hrHPV
infections attributable to HPV 16, 35, and 33 were significantly
higher in women with CIN 2,3 than in women with WNL/CIN 1
(p,0.03). In contrast, the proportions of hrHPV infections
attributable to HPV 56, 59, 51, and 68 were significantly lower
in women with CIN 2,3 than in women with WNL/CIN 1
(p,0.04). Considering the specific contribution of HPV types 16
and/or 18 (HPV 16/18), 27.1% of women had one or both of
these hrHPV types. HPV 16/18 contributed to 48.6% of hrHPV
infections among women with CIN 3, 31.2% among women with
CIN 2, 25.0% among women with CIN 1, and 25.4% among
women with WNL (Table 2).
Figure 3 shows the age- and disease-specific distribution of
genotypes using all hrHPV infections as the denominator. HPV 35
and 16 remained the most common hrHPV genotypes in all age
Figure 1. Age-specific high-risk HPV DNA prevalence (Hybrid Capture 2) by cervical disease status among 8,050 HIV-negative
women in Khayelitsha, South Africa.
doi:10.1371/journal.pone.0044332.g001
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and disease groups. HPV 16 was more common than HPV 35 in
older women (40–65 years) with or without cervical disease. In
women with WNL/CIN 1, HPV 16 showed a significant trend
towards increasing frequency with increasing age (p-trend = 0.01).
In women with CIN 2,3, HPV 45 showed a significant trend
towards increasing frequency with increasing age (ptrend = 0.02).
Only HPV 68 showed a significant decline in frequency with
increasing age in women with WNL/CIN 1 (ptrend = 0.04).
Considering the contribution of HPV16/18 to all hrHPV
infections, HPV16/18 made up 35.0%, 23.0%, 17.4%, and
19.7% in women with CIN 3, CIN 2, CIN 1 and WNL,
respectively.
Multiple hrHPV Genotypes
Table 3 shows the frequency of multiple hrHPV genotypes by
age and cervical disease status among women with at least one
hrHPV genotype detected. Among these 1,239 women, 24% had
multiple hrHPV genotypes detected, with some women having as
many as 6 different hrHPV genotypes. The most common hrHPV
genotypes among women with multiple types were the following in
descending order: HPV 35, HPV 16, and HPV 58. Out of the 301
women with multiple HPV genotypes, co-infection with HPV 35
and HPV 16 was the most common followed by co-infection with
HPV 35 and HPV 58. Younger women (17–29 years) were more
likely to have multiple hrHPV genotypes than older women (30–
65 years) overall (p,0.0001) and within each cervical disease
group (p,0.01). Cervical disease status was unrelated to multiple
hrHPV types, controlling for age.
Discussion
Our study provides a comprehensive description of the profile of
hrHPV infections among a large cohort of HIV-negative women
in South Africa. We found that hrHPV infection is common
among this population, with HPV 16 and 35 being the most
common high-risk genotypes. Younger women had the highest
burden of hrHPV infections and were more likely to be infected
with multiple high-risk genotypes than older women. Interestingly,
the proportion of cervical disease attributable to different HPV
genotypes differed across age groups. Specifically, HPV 35, HPV
16, and HPV 45 made a relatively larger contribution to advanced
cervical disease in older relative to younger women.
Overall the observed prevalence of hrHPV in HIV-negative
women was 20.7% in our study. Compared to other studies using
Figure 2. Age- and genotype-specific prevalence of the 6 most common high-risk HPV genotypes among 8,050 HIV-negative
women.
doi:10.1371/journal.pone.0044332.g002
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the same assay, hrHPV prevalence in our study was higher than
reported in developed countries like Spain (10.7%) [16] and the
U.S. (14.3%) [17], but lower than reported in Denmark (22.8%)
[18]. Relative to studies conducted in Sub-Saharan Africa, the
hrHPV prevalence in our study population fell between the
prevalence of 10.2% reported among HIV-negative Ugandan
women, aged 15–59 years [19] and 27.6% among HIV-negative
Zimbabwean women, aged 25–55 years [20]. Age differences
across the studies make comparisons difficult but differences across
populations may be due to sexual behavior. Our finding of higher
prevalence among younger women is consistent with most other
studies [19,20]. A possible explanation could be that younger
women are more sexually-active, and therefore exposed to more
hrHPV types than older women. The decrease of hrHPV
prevalence with increasing age could also reflect clearance of
hrHPV infections over time [21,22].
As expected, the prevalence of hrHPV, all high-risk genotypes
collectively and specific high-risk genotypes separately, was higher
among women with CIN 2,3 than among women with WNL/
CIN1. The prevalence of hrHPV DNA among women with
advanced disease was .80%, similar to that reported from many
studies and meta-analyses of women in Africa and other parts of
the world [4]. Among women with CIN 2,3, a slight bi-modal
curve of hrHPV prevalence was observed across age groups: the
first peak among younger women, aged ,20 years, and a second
peak among older women. The slight reduction in hrHPV
prevalence observed among middle-aged women with CIN2,3
may be a result of difficulties for the pathologist to discriminate
between true CIN 2,3 and its histological mimics. Previously we
have shown that many of the hrHPV negative CIN 2,3 lesions
included in this analysis stain negatively for p16 and therefore
appear to be histological mimics of CIN 2,3 [23]. Moreover, a
recent study that found an apparent reduction in the prevalence of
hrHPV in CIN 2,3 lesions with increasing age documented that
many of the hrHPV negative lesions diagnosed as CIN 2,3 were
also negative for p16 [24]. This interpretation is further
strengthened by the finding that in the current study the bi-modal
curve was difficult to discern in women with CIN 3 which is a
more robust histological diagnosis than is CIN 2. Other possible
explanations for the second peak of positivity among older women,
which has been reported in previous studies [25,26], may include
changes in sexual behavior, a cohort effect, or HPV reactivation as
a result of age-related declines in immune function or hormonal
levels [27].
In this large South African population, HPV 35 and 16 were the
two most common hrHPV genotypes, regardless of cervical disease
status. Other studies conducted in Sub-Saharan Africa, including
in South Africa [28,29], Kenya [30], and Nigeria [31] also showed
that HPV 35 was equal to or more common than HPV 16 among
women with or without cervical disease. However, for the majority
of these studies, HIV status was not known [28,29,30,31]. In
addition, we found that women with multiple high-risk genotypes
were more likely to be infected with HPV 35 than any other high-
risk type. Globally, HPV 35 has not been reported as the most
common high-risk genotype among women with or without
cervical disease [4,9,10,27]; and, current HPV vaccines do not
cover or produce significant cross-protection for this high-risk type
[32,33]. Therefore, women who are given the current vaccines are
not protected against HPV 35, a high-risk type that is prevalent in
Sub-Saharan Africa and is associated with cervical disease. We did
not observe HPV 35 among the small number of invasive cancer
cases were are able to test. The role of HPV35 in invasive cervical
cancer among women in this region needs further investigation.
The prevalence of HPV 16 and 45 increased with age among
women with CIN 2,3; and, these two types constituted a greater
proportion of the high-risk infections in older women. The greater
Table 2. Distribution of specific high-risk HPV genotypes among 1,239 HIV-negative women with a high-risk genotype detected
by PCR.
WNL CIN 1 CIN 2 CIN 3
P-value
(WNL/CIN 1 vs CIN 2,3)
# Women with a HR Types 902 172 93 72 –
# of isolates 1164 247 126 100 –
N (%) Genotype
Type 16 146 (16.19) 23 (13.37) 21 (22.58) 29 (40.28) ,0.0001
Type 35 151 (16.74) 41 (23.84) 29 (31.18) 14 (19.44) 0.0125
Type 33 67 (7.43) 15 (8.72) 12 (12.90) 9 (12.50) 0.0274
Type 45 106 (11.75) 19 (11.05) 7 (7.53) 12 (16.67) 0.9632
Type 58 115 (12.75) 14 (8.14) 13 (13.98) 9 (12.50) 0.6288
Type 31 72 (7.98) 17 (9.88) 8 (8.60) 9 (12.50) 0.3886
Type 18 85 (9.42) 22 (12.79) 9 (9.68) 8 (11.11) 0.8921
Type 52 90 (9.98) 21 (12.21) 12 (12.90) 3 (4.17) 0.6225
Type 39 51 (5.65) 7 (4.07) 1 (1.08) 2 (2.78) 0.0516
Type 56 56 (6.21) 15 (8.72) 3 (3.23) 1 (1.39) 0.0346
Type 59 65 (7.21) 14 (8.14) 2 (2.15) 1 (1.39) 0.0041
Type 51 75 (8.31) 23 (13.37) 5 (5.38) 1 (1.39) 0.0179
Type 68 85 (9.42) 16 (9.30) 4 (4.30) 2 (2.78) 0.0141
Types 16/18 229 (25.39) 43 (25.00) 29 (31.18) 35 (48.61) 0.0003
Note: WNL=within normal limits, CIN 1 = cervical intraepithelial neoplasia grade 1, CIN 2= cervical intraepithelial neoplasia grade 2, CIN 3= cervical intraepithelial
neoplasia grade 3, HPV=Human papillomavirus, HC2 =Hybrid capture 2, HR =high-risk, 16/18 =HPV 16 and/or HPV 18, PCR = Polymerase chain reaction.
doi:10.1371/journal.pone.0044332.t002
High-Risk HPV Genotypes among Women
PLOS ONE | www.plosone.org 6 September 2012 | Volume 7 | Issue 9 | e44332
High-Risk HPV Genotypes among Women
PLOS ONE | www.plosone.org 7 September 2012 | Volume 7 | Issue 9 | e44332
proportion of CIN 2,3 lesions associated with HPV 16 with
increasing age observed in this South African population contrasts
with the reduction in HPV 16 infections in CIN 2,3 lesions with
increasing age that was recently reported from North America
[24]. The reasons for these differential age interactions with HPV
16 are unclear but may relate to the fact that the South African
women had not been previously screened whereas the North
American women were a well-screened cohort. Other studies have
shown that HPV 16-associated lesions are larger and presumably
easier to detect through screening than lesions associated with
other hrHPV genotypes [34]. For HPV 35, neither the prevalence
nor the proportional contribution of this high-risk type differed by
age among women with more advanced disease. Younger women,
aged 17–29 years, had a wider variety of high-risk HPV genotypes,
including HPV 35, and an equal distribution of HPV 33, HPV 31,
HPV 18, and HPV 16, which may be due to increased sexual
exposure to more hrHPV types than older women.
HPV 16 and/or 18, the high-risk types included in the licensed
vaccines and reported to be the most prevalent high-risk HPV
types worldwide, accounted for high risk infections among 25.4%
of women without disease but 48.6% of high risk infections among
women with CIN 3. These statistics under-estimate the value of
the current vaccines as the contribution of HPV 16 and 18 is
greater when analysis is restricted to cervical cancer cases. HPV 16
and 18 are highly associated with invasive cervical cancer,
comprising together .70% of HPV types detected in this disease
group, worldwide [4,5,35]. A significant limitation of our study is
that only a small number of invasive cervical cancer cases were
identified during screening limiting our capacity to comment on
the hrHPV genotype distributions in this group. Meta-analyses
have shown Africa as the only geographical area in which HPV 35
was among the top 5 most common hrHPV genotypes in women
with invasive cervical cancer [4,5]; the reason for this higher
prevalence in Africa compared to other regions is not known but
may relate to host genetic differences. Our results suggest that next
generation vaccines that include HPV 35 could have significant
impact on the decrease of cervical diseases in Sub-Saharan Africa.
We observed that younger women (17–29 years) were more
likely to have multiple hrHPV genotypes compared to older
women ($30 years), regardless of cervical disease status. This
observation is consistent with other studies that have examined
multiple high-risk genotypes among younger versus older women
[25,36]. This higher frequency of multiple hrHPV genotypes
among younger women may be due sexual activity and larger
numbers of partners. Some studies have shown multiple HPV
genotypes to be associated with HPV persistence [22,37] which
suggesting that they could contribute to the development of
cervical neoplasia. However, in our study, multiple hrHPV
infections were not associated with cervical disease after control-
ling for age.
There are limited data on the prevalence and distribution of
specific high-risk HPV genotypes among HIV negative women in
Sub-Saharan Africa populations by age and cervical disease. Our
study population is large and HIV and cervical disease status were
rigorously ascertained providing a comprehensive description of
high-risk HPV genotypes among HIV negative women in South
Africa. One limitation of the study was that some women were
excluded in the final analysis as their cervical disease status could
not be classified. However, these exclusions were limited (,6% of
the total cohort) and therefore unlikely to have affected the
estimates. A second limitation was that HPV DNA negative
women in Cohort 1 with a negative cytology did not have a
colposcopy performed; as a result, cervical disease could have been
missed in this group. However, our Cohort 2 women who were
HPV negative and had a negative cytology did not have cervical
disease detected by colposcopy which gives us confidence that
cervical disease was unlikely to have been missed in Cohort 1.
Another limitation is that PCR genotyping was only conducted on
the samples that were HC2 positive. Since the HC2 assay is
unlikely to be 100% specific to detect HPV DNA, some of the
samples that were HC2 positive but had no detectable genotype
may have been truly hrHPV negative. However, it is more likely
that much of this discrepancy is explained by the less than perfect
sensitivity of the genotyping assay and the fact that for genotyping
Figure 3. Distribution of high-risk HPV genotypes among 1,637 high-risk HPV infections in 1,239 women (i.e. a woman may have
more than one type) by disease status and age.
doi:10.1371/journal.pone.0044332.g003
Table 3. Multiple high-risk types among 1,239 HIV-negative women with a high-risk HPV genotype by age and disease status.
Disease Status Age
N with at least
1 HR type Median (range) N with 1 Type (%) N with 2+ Types (%) P-value
All 17–29 years
(reference group)
435 1 (1–6) 281 (64.60%) 154 (35.40%) –
30–39 years 420 1 (1–4) 337 (80.24%) 83 (19.76%) ,0.0001
40–65 years 384 1 (1–4) 320 (83.33%) 64 (16.67%) ,0.0001
WNL/CIN 1 17–29 years 403 1 (1–6) 264 (65.51%) 139 (34.49%) –
30–39 years 358 1 (1–4) 288 (80.45%) 70 (19.55%) ,0.0001
40–65 years 313 1 (1–3) 264 (84.35%) 49 (15.65%) ,0.0001
CIN 2/CIN 3 17–29 years 32 1 (1–6) 17 (53.13%) 15 (46.88%) –
30–39 years 62 1 (1–3) 49 (79.03%) 13 (20.97%) 0.0093
40–65 years 71 1 (1–4) 56 (78.87%) 15 (21.13%) 0.0078
Total Study
Population
1239 1 (1–6) 939 (75.71%) 301 (24.29%) –
Note: WNL =within normal limits, CIN 1 = cervical intraepithelial neoplasia grade 1, CIN 2= cervical intraepithelial neoplasia grade 2, CIN 3= cervical intraepithelial
neoplasia grade 3, HPV=Human papillomavirus.
doi:10.1371/journal.pone.0044332.t003
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we utilized archived samples that were several years old. We made
the simplest possible assumptions in calculating the distribution
and prevalence of specific types within the limitations of these
current assays. Assay performance is unlikely to differ by genotype,
[38] thus the higher than expected proportion with HPV35 is
unlikely to be due to bias of the PCR assay used.
Our estimates may be biased but there is no evidence to suggest
this to be the case. Measurement of HPV status and determination
of cervical disease status at different time points, in particular, with
Cohort 2, may be a limitation if HPV infection cleared before
cervical disease ascertainment; as a result, we could have slightly
over-estimated the hrHPV prevalence in women without disease.
Finally, we had only a small number of invasive cervical cancer
cases limiting our capacity to comment on the genotype
distribution in this group.
Conclusion
In this large cohort of HIV negative South African women
spanning a wide age range from 18 to 65 years, HPV 16 and 35
were the most prevalent hrHPV genotypes, regardless of cervical
disease status. Younger women had exceedingly high rates of
hrHPV infection and could benefit from receiving the HPV
vaccine prior to initiating sexual activity. We also observed
interesting age relationships with HPV types 16 and 45
constituting a larger proportion of the infection burden in older
relative to younger women with CIN 3. Although the currently-
approved vaccines targeting HPV 16 and 18 could have a
substantial impact on cervical disease in this population if initiated
before their sexual debut, next generation vaccines that include
other hrHPV genotypes, especially HPV 35 and HPV 45, will
further reduce HPV infections in a population that is at high risk
for advanced cervical disease and invasive cervical cancer.
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